HUM stock forecast, quote, news & analysis

Key Takeaways

• Humana (HUM) shares rose approximately 10.4% over the last 30 days, climbing from $360.65 on June 18 to $398.28 as of July 20, 2026.
• The stock has staged a dramatic rally over the last quarter, surging roughly 89% from $210.34 in late April, driven by improving Medicare Advantage sentiment, strong Q1 earnings, and a wave of analyst upgrades.
• Wells Fargo's upgrade to Overweight with a $502 price target on July 13 served as a major catalyst, citing moderating medical cost trends in Medicare Advantage.
• Zacks Research upgraded HUM to Strong-Buy in mid-July, while multiple firms — including Mizuho, RBC, Evercore, and Truist — raised price targets significantly over the past 30 to 60 days.
• Humana's Q2 2026 earnings report, expected July 29, is the next pivotal event for investors, with consensus estimates pointing to EPS of approximately $6.17–$6.78.

Humana Inc. (HUM) Company Overview and Market Position

Humana Inc. is a Louisville, Kentucky-based health insurance company and one of the largest Medicare Advantage providers in the United States. The company offers a broad portfolio of health insurance products, including Medicare Advantage plans, standalone prescription drug (Part D) coverage, Medicaid managed care programs, and commercial group health plans. Through its CenterWell segment, Humana also operates primary care clinics, pharmacy services, and home health operations, creating an integrated care delivery platform. With approximately $48 billion in market capitalization and annual revenues projected to exceed $162 billion in fiscal 2026, Humana is a dominant force in the government-sponsored healthcare market and a closely watched barometer for Medicare cost trends, regulatory policy shifts, and the broader managed care sector.

Humana Inc. (HUM) Stock Price Performance: Last 30 Days vs. Quarter

Over the past 30 calendar days, Humana shares have advanced approximately 10.4%, rising from a closing price of $360.65 on June 18, 2026, to $398.28 as of July 20. The stock has been on a sustained uptrend since mid-June, punctuated by periodic consolidation and a sharp but short-lived pullback on July 16, when shares dropped from $407.78 to $386.48 in a single session before rebounding quickly above $400.

The 30-day gain is part of a far larger move. Over the last quarter, HUM has surged roughly 89%, rocketing from $210.34 on April 20 to nearly $400. The quarterly rally gained momentum following Humana's Q1 2026 earnings release on April 29, which delivered EPS of $10.31 — well above the $9.97 consensus — on revenue of $39.65 billion. The stock rose 5.8% that day and has not looked back, supported by a significant shift in analyst sentiment and easing fears around Medicare Advantage medical cost trends.

What Drove HUM Stock Price in the Last 30 Days

Several converging catalysts fueled Humana's 30-day advance. The most impactful development came on July 13, when Wells Fargo upgraded the stock to Overweight from Equal-Weight and raised its price target from $227 to $502 — a signal that resonated strongly with institutional investors. Analyst Stephen Baxter cited moderating Medicare Advantage cost trends as the core reason, writing that earlier concerns about underwriting and membership growth had meaningfully diminished.

Around the same time, Zacks Research upgraded HUM to Strong-Buy and raised earnings estimates across multiple periods, including FY2026 EPS to $9.04 and FY2027 EPS to $13.30. Additional analyst support came from RBC, which lifted its target to $415, and Truist, which also set a $415 target. Cantor Fitzgerald raised its target to $300 in early July while noting that Humana's Q2 Medicaid enrollment data trended favorably relative to peers.

Broader sector tailwinds also helped. Improving CMS benchmark funding, higher Part D subsidies under the Inflation Reduction Act, and a more favorable reimbursement backdrop contributed to renewed investor confidence. Humana's growing state-based Medicaid contract portfolio — including the Illinois HealthChoice statewide award expected to launch in January 2027 — reinforced the narrative of diversification beyond Medicare Advantage.

What Drove HUM Stock Performance Over the Last Quarter

Humana's extraordinary quarterly rally reflects both a powerful earnings-driven reset and a broader repricing of managed care risk. The Q1 2026 beat on April 29 served as the inflection point, proving that Humana could deliver strong profitability even amid elevated medical utilization. Over the following weeks, analysts who had been cautious — including Morgan Stanley and Robert W. Baird — raised targets, though some maintained cautious ratings.

Underlying the rally is a fundamental improvement in the Medicare Advantage reimbursement environment. CMS benchmark payment rates, the Inflation Reduction Act's Part D redesign, and stabilizing utilization patterns have all contributed to a more constructive outlook. Additionally, Humana's CenterWell platform — encompassing primary care, pharmacy, and home health — has demonstrated scalable growth, adding over 110,000 sequential patients in Q1 2026 alone. The combination of improving insurance margins and a fast-growing care delivery business has reshaped the investment narrative from one of cost pressure to one of earnings recovery and long-term compound growth.

Trending AI Robots

For investors looking to complement their own research with data-driven insights, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron operates hundreds of AI-driven trading robots that collectively analyze thousands of stocks across diverse strategies, timeframes, and risk profiles. Only the top-performing and most relevant bots earn placement in the Trending section, making it a streamlined way for traders to discover quantitative approaches that align with current market conditions. Bots vary by strategy — from swing trading to long-term trend following — and come with transparent performance metrics and trade histories. Exploring the Trending AI Robots page can help traders identify systematic approaches that fit their investment style.

HUM Stock Forecast Drivers: What Investors Should Watch Next

Humana's Q2 2026 earnings report, scheduled for July 29, is the most immediate catalyst. Analysts expect EPS in the range of $6.17 to $6.78, compared with $6.27 a year ago, on revenue of roughly $40.6 billion. The market will focus closely on the insurance segment's benefit ratio, Medicare Advantage membership trends, and any updates to full-year 2026 guidance.

Beyond earnings, several factors warrant attention. CMS Stars ratings litigation remains an unresolved overhang, with potential implications for 2027 revenue. Medical cost trend trajectories will be scrutinized in the context of an aging population and post-pandemic utilization normalization. The integration and scaling of CenterWell — particularly the MaxHealth acquisition — will serve as a barometer for Humana's diversification strategy. Additionally, macroeconomic factors such as interest rate policy and healthcare regulatory developments under the current administration could influence sentiment. With the stock trading near $400 after a nearly 90% quarterly surge, execution on earnings and guidance will be critical to sustaining momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations